Parallel Symposia

Thursday, September 8th

PFIZER (Amphitheater)

07h30 - 8h15

Optimal management of patients with acromegaly: practical considerations

7:45-7:50 Opening remarks (Chairman)

7:50-8:05 Optimizing biochemical control of acromegalic patients: from clinical studies to real life (speaker 1, TBC)

8:05-8:20 Challenges of diabetes in acromegaly: a clinical case (speaker 2, TBC)

8:20-8:30 Q&A and closing remarks (Chairman)

RECORDATI (Amphitheater)

12h30 - 14h00

12:30–12:35 Welcome and introduction (Mônica Gadelha, MG: Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil)

Cushing’s syndrome clinic

12:35–12:40 Framing the use of medical therapy in Cushing’s syndrome (Rosario Pivonello, RP: Università Federico II di Napoli, Naples, Italy)

12:40–12:45 Canvassing the treatment landscape for Cushing’s syndrome (Antoine Tabarin, AT: University Hospital of Bordeaux, Bordeaux, France)

12:45–13:10 Clinical snapshots: Considerations for practical management of patients with Cushing’s syndrome (Rosario Pivonello and Antoine Tabarin)

Format: Guided case discussion

Acromegaly clinic

13:10–13:15 Framing the use of medical therapy in uncontrolled acromegaly (Diego Ferone, Endocrinology Unit, IRCCS Policlinico San Martino, University of Genova, Italy)

13:15–13:20 Canvassing the treatment landscape for acromegaly (Mônica Gadelha)

13:20–13:45 Clinical snapshots: Considerations for practical management of patients with acromegaly (Mônica Gadelha and Diego Ferone)

13:45–14:00 Q&A and close (All faculty, moderated by Mônica Gadelha)

FRIDAY, September 9th


08h00 - 8h45

Diagnosis of Growth Hormone (GH) disorders: What's new in 2022 ?

Chair: Thierry Brue (France)

IGF-I in the diagnosis of GH disorders. Martin Bidlingmaier (Germany)

Benefits and limitations of dynamic stimulation tests.  Philippe Chanson (France)

IPSEN (Rhône 3)

08h00 - 8h45

Tailored approach to complex patient care: Updates on somatostatin receptor ligands (SRLs)

2 mins Welcome and Introduction (Marta Korbonits, Queen Mary, University of London, UK (Chairperson))

8 mins Treating patients outside of the hospital: Independent injection vs healthcare-settings (Marta Korbonits)

10 mins Exploring the use of extended duration intervals (EDI) in acromegaly (Maria Fleseriu, Oregan Health and Science University, Portland, USA)

10 mins Evolving care to meet patient and nurse needs (Sofia Llahana, University of London, UK)

5 mins Key takeaways (Marta Korbonits)

10 mins (Q&A, Facilitated by Marta Korbonits)

HRA PHARMA (Rhône 3)

12h30 - 14h00

Managing Cushing’s syndrome through experience: Real-world insights

Chair: Antoine Tabarin

Treating mild hypercortisolism in patients with bilateral macronodular adrenal hyperplasia – Valentina Morelli

Controlling Cushing’s disease in the long-term with medical treatment – Olivier Chabre

New insights into Cushing’s syndrome: The patient’s perspective – Elena Valassi

Q&A session – All speakers

AMRYT (Rhône 2)

12h30 - 14h00

More than Just a Numbers Game: Comprehensive Treatment to Address the Burden of Acromegaly

  1. Introduction by chair (5 mins)
  2. Challenges in the current treatment of acromegaly (25 mins) [Speaker to be confirmed]
  • Disease pathogenesis and burden of disease
  • Challenges of diagnosis
  • Treatment options including medical therapy
  • Burdens of current treatments
  • Persistent and breakthrough symptoms
  • Discordance between HCP and patient in perceived disease and treatment burden
  • Acromegaly Voice of the Patient report
  1. Overview of current treatment paradigm (25 mins) [Speaker to be confirmed]
  • An overview of the Pituitary Society guidelines for the treatment of acromegaly
  • Recent advancements medical therapies for treatment of acromegaly
  • Patient case(s)
  1. Improvement beyond biochemical control (25 mins) [Speaker to be confirmed]
  • Efficacy and safety data from the oral octreotide clinical program
  • Correlation of biochemical control with other patient outcomes
  • Impact of medical therapies (including oral octreotide) on comorbidity burden, symptom burden and quality of life
  1. Q&A session and call to action (10 mins) [moderated by Chair]